The results showed that tiplaxtinin inhibited the CFC production of CML CD34+ cells in a dose-dependent manner and exhibited a stronger inhibitory effect on leukemic cells than on normal control cells (Fig. 5D). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.